Pelthos Therapeutics Inc's Comment on Supply Chain
The Company sources raw materials, including nitric oxide gas, from a limited number of qualified third-party suppliers. Raw materials are converted into active pharmaceutical ingredient (API) at the Company's primary operating facility in North Carolina, which is fully validated and qualified, and utilizes an integrated Quality Management System and ERP platform. The API is then sent to a third-party contract manufacturing organization (CMO) for conversion into the finished product, ZELSUVMI. Finished products are shipped from the CMO to a U.S.-based third-party logistics provider for distribution. The Company relies on third-party logistics vendors for transportation of raw materials, API, and finished products, noting that some materials have hazard classifications that may impact transportation. To mitigate supply chain risks, the Company maintains redundancy planning and minimum API inventory. Manufacturing API at its U.S.-based facility enables critical control over this complex supply chain component.
Pelthos Therapeutics Inc's Comment on Supply Chain
The Company sources raw materials, including nitric oxide gas, from a limited number of qualified third-party suppliers. Raw materials are converted into active pharmaceutical ingredient (API) at the Company's primary operating facility in North Carolina, which is fully validated and qualified, and utilizes an integrated Quality Management System and ERP platform. The API is then sent to a third-party contract manufacturing organization (CMO) for conversion into the finished product, ZELSUVMI. Finished products are shipped from the CMO to a U.S.-based third-party logistics provider for distribution. The Company relies on third-party logistics vendors for transportation of raw materials, API, and finished products, noting that some materials have hazard classifications that may impact transportation. To mitigate supply chain risks, the Company maintains redundancy planning and minimum API inventory. Manufacturing API at its U.S.-based facility enables critical control over this complex supply chain component.
Sources:
Pelthos Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Pelthos Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
